Top

Published in:

01-09-2014 | Research Article

A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition

Published in: Tumor Biology | Issue 9/2014

Abstract

Gallbladder cancer (GBC) is a violent neoplasm associated with late diagnosis, unsatisfactory treatment, and poor prognosis. The disease shows complex interplay between multiple genetic variants. We analyzed 15 polymorphisms in nine genes involved in various pathways to find out combinations of genetic variants contributing to GBC risk. The genes included in the study were matrix metalloproteinases (MMP-2, MMP-7, and MMP-9), tissue inhibitor of metalloproteinases (TIMP-2), cytochrome P450 (CYP)1A1, CYP1B1, phospholipase C epsilon 1 (PLCE1), liver X receptor (LXR)-alpha, and LXR-beta. Genotypes were determined by PCR-RFLP and TaqMan probes. Statistical analysis was done by SPSS version 16. Multilocus analysis was performed by Classification and Regression Tree (CART) analysis and multifactor dimensionality reduction (MDR) to gene–gene interactions in modifying GBC risk. In silico analysis was done using various bioinformatics tools (F-SNP, FAST-SNP). Single locus analysis showed association of MMP-2 (−735 C > T, −1306 C > T), MMP-7 − 181 A > G, MMP-9 (P574R, R668Q), TIMP-2 − 418 G > C, CYP1A1-MspI, CYP1A1-Ile462Val, PLCE1 (rs2274223 A > G, rs7922612 T > C) and LXR-beta T > C (rs3546355 G > A, rs2695121 T > C) polymorphisms with GBC risk (p < 0.05) whereas CYP1B1 and LXR-α variants were not associated with GBC risk. Multidimensional reduction analysis revealed LXR-β (rs3546355 G > A, rs2695121 T > C), MMP-2 (−1306 C > T), MMP-9 (R668Q), and PLCE1 rs2274223 A > G to be key players in GBC causation (p < 0.001, CVC = 7/10). The results were further supported by independent CART analysis (p < 0.001). In silico analysis of associated variants suggested change in splicing or transcriptional regulation. Interactome and STRING analysis showed network of associated genes. The study found PLCE1 and LXR-β network interactions as important contributory factors for genetic predisposition in gallbladder cancer.

Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167–76.CrossRefPubMed

Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer J Int Cancer. 2006;118:1591–602.CrossRef

Eslick GD. Epidemiology of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:307–30. ix.CrossRefPubMed

Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRefPubMed

Srivastava K, Srivastava A, Sharma KL, Mittal B. Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat Res. 2011;728:67–79.PubMedCentralCrossRefPubMed

Sharma KL, Misra S, Kumar A, Mittal B. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int. 2012;32:1278–86.CrossRefPubMed

Sharma KL, Umar M, Pandey M, Misra S, Kumar A, Kumar V, Mittal B. Association of potentially functional genetic variants of plce1 with gallbladder cancer susceptibility in north indian population. J Gastrointest Cancer. 2013.

Sharma KL, Misra S, Kumar A, Mittal B. Association of liver x receptors (LXRs) genetic variants to gallbladder cancer susceptibility. Tumour Biol. 2013.

Sharma KL, Agarwal A, Misra S, Kumar A, Kumar V, Mittal B. Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility. Tumour Biol.

10.

Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactions. Bioinformatics. 2003;19:376–82.CrossRefPubMed

11.

Lee PH, Shatkay H. F-SNP: Computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008;36:D820–4.PubMedCentralCrossRefPubMed

12.

Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34:W635–41.PubMedCentralCrossRefPubMed

13.

Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 2010;42:759–63.CrossRefPubMed

14.

Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in plce1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010;42:764–7.PubMedCentralCrossRefPubMed

15.

Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet. 2011;43:679–84.CrossRefPubMed

16.

Cui XB, Chen YZ, Pang XL, Liu W, Hu JM, Li SG, et al. Multiple polymorphisms within the PLCE1 are associated with esophageal cancer via promoting the gene expression in a Chinese Kazakh population. Gene. 2013;530:315–22.CrossRefPubMed

17.

Chen YZ, Cui XB, Hu JM, Zhang WJ, Li SG, Yang L, et al. Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness. APMIS. 2013;121:908–18.CrossRefPubMed

18.

Hao NB, He YF, Zhang D, Luo G, Chen BJ, Zhang Y, et al. PLCE1 polymorphism and upper gastrointestinal cancer risk: a meta-analysis. PLoS One. 2013;8:e67229.PubMedCentralCrossRefPubMed

19.

Umar M, Upadhyay R, Mittal B. PLCE1 rs2274223 A>G polymorphism and cancer risk: A meta-analysis. Tumour Biol. 2013.

20.

Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141:50–61.CrossRefPubMed

21.

Gabbi C, Kim HJ, Barros R, Korach-Andre M, Warner M, Gustafsson JA. Estrogen-dependent gallbladder carcinogenesis in LXRβ^−/−female mice. Proc Natl Acad Sci U S A. 2010;107:14763–8.PubMedCentralCrossRefPubMed

22.

Infante J, Rodriguez-Rodriguez E, Mateo I, Llorca J, Vazquez-Higuera JL, Berciano J, et al. Gene–gene interaction between heme oxygenase-1 and liver X receptor-β and Alzheimer's disease risk. Neurobiol Aging. 2010;31:710–4.CrossRefPubMed

23.

Pommier AJ, Dufour J, Alves G, Viennois E, De Boussac H, Trousson A, et al. Liver X receptors protect from development of prostatic intra-epithelial neoplasia in mice. PLoS Genet. 2013;9:e1003483.PubMedCentralCrossRefPubMed

24.

Dahlman I, Nilsson M, Gu HF, Lecoeur C, Efendic S, Ostenson CG, et al. Functional and genetic analysis in type 2 diabetes of liver X receptor alleles—a cohort study. BMC Med Genet. 2009;10:27.PubMedCentralCrossRefPubMed

25.

Wang J, Einarsson C, Murphy C, Parini P, Bjorkhem I, Gafvels M, et al. Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid-depleted mice. J Lipid Res. 2006;47:421–30.CrossRefPubMed

26.

El Roz A, Bard JM, Huvelin JM, Nazih H. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast cancer cells: Relation to proliferation and apoptosis. Anticancer Res. 2012;32:3007–13.PubMed

27.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer. 75:235-241.

28.

Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res. 2003;1:420–7.PubMed

29.

Perigny M, Bairati I, Harvey I, Beauchemin M, Harel F, Plante M, et al. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 2008;129:226–31.CrossRefPubMed

30.

Wang JH, Li LF, Yu Y, Li B, Jin HJ, Shen DH, et al. Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer. Oncol Rep. 2012;27:775–82.PubMed

31.

Koyama S. Intracellular localization of matrix metalloproteinases and their inhibitors in cultured tumor cell lines: flow cytometric analysis. Oncol Rep. 2006;15:735–8.PubMed

32.

Decock J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet. 2008;73:197–211.CrossRefPubMed

33.

Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, Zhang X, et al. Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat. 2007;28:1091–7.CrossRefPubMed

34.

Qiu W, Zhou G, Zhai Y, Zhang X, Xie W, Zhang H, et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2008;17:2514–8.CrossRefPubMed

35.

Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the "Hemopexin" domain? Matrix Biol. 1997;15:511–8.CrossRefPubMed

36.

Trojanek J. matrix metalloproteinases and their tissue inhibitors. Postepy Biochem. 2012;58:353–62.PubMed

37.

Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–93.CrossRefPubMed

Title: A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition
Publication date: 01-09-2014
Published in: Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2094-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer

RETRACTED ARTICLE: FBXL5 targets cortactin for ubiquitination-mediated destruction to regulate gastric cancer cell migration

Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma

Germline mutations of TP53 gene in breast cancer

RETRACTED ARTICLE: Relationships between genetic polymorphisms in inflammation-related factor gene and the pathogenesis of nasopharyngeal cancer

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer